ReviewCells2024
Metabolomics-Driven Biomarker Discovery for Breast Cancer Prognosis and Diagnosis.
Review in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- NMR-based metabolomics analysis in breast cancer patients from Saudi Arabia: a pilot study.Scientific reports · 2026Article
- Salivary Metabolic Characteristics and Response to Neoadjuvant Systemic Therapy in Breast Cancer.International journal of molecular sciences · 2026Article
- Integrative proteomics and metabolomics advance early cancer detection and targeted therapy with emerging technologies and clinical applications.Discover oncology · 2026Review
- The Role of Gut Microbiota in Postmenopausal Women: Implications for Lipid Metabolism and Targeted Nutritional Interventions.Current nutrition reports · 2026Review
- Harnessing endophytes and Multi-Omics for sustainable Colchicine biosynthesis.World journal of microbiology & biotechnology · 2026Review
- Metabolomic-driven prediction of the mutational status of healthy individuals with a family history of hereditary breast and ovarian cancer syndrome: the HRRmet study.Scientific reports · 2026Article
- Metabolic Signatures of Breast Cancer Subtypes and the Metabolic Impact of Chemotherapy.Metabolites · 2026Article
- Metabolic profiling of human melanoma cell lines with high and low metastatic capacity by 1H-NMR spectroscopy.PloS one · 2026Article
- Metabolomics-based exploration of the pathogenesis of breast cancer-related fatigue and progress of traditional Chinese medicine intervention.Frontiers in oncology · 2026Review
- Therapeutic potential of selenium in breast cancer: targeting apoptosis and proliferation pathways.Annals of medicine and surgery (2012) · 2026Review
- Cooperative CCL2/CCR2 and HGF/MET signaling enhances breast cancer growth and invasion associated with metabolic reprogramming.Cancer biology & therapy · 2025Article
- Metabolomics and Pharmacometabolomics: Advancing Precision Medicine in Drug Discovery and Development.Metabolites · 2025Review
- Metabolomics as a tool for understanding and treating triple-negative breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Exosomal transfer of miR-223-3p from carcinoma-associated fibroblasts promotes the malignant properties and chemoresistance of colon cancer cells by targeting NF2/Hippo signaling.Medical oncology (Northwood, London, England) · 2025Article
- Review
- Targeted Metabolomic Serum Analysis of Patients with High and Low Risk of Endometrial Cancer Recurrence and Positive and Negative Lymph Node Status.Metabolites · 2025Article
- The Associations of Serum Folate Forms with Metabolic Dysfunction-Associated Fatty Liver Disease and Liver Fibrosis: A Nationwide Cross-Sectional Study.Metabolites · 2025Article
- Recent advances in applications of artificial intelligence-assisted Raman spectroscopy in diagnosis of cancers.Frontiers in molecular biosciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a cancer with global prevalence and a surge in the number of cases with each passing year. With the advancement in science and technology, significant progress has been achieved in the prevention and treatment of breast cancer to make ends meet. The scientific intradisciplinary subject of "metabolomics" examines every metabolite found in a cell, tissue, system, or organism from different sources of samples. In the case of breast cancer, little is known about the regulatory pathways that could be resolved through metabolic reprogramming. Evidence related to the significant changes taking place during the onset and prognosis of breast cancer can be obtained using metabolomics. Innovative metabolomics approaches identify metabolites that lead to the discovery of biomarkers for breast cancer therapy, diagnosis, and early detection. The use of diverse analytical methods and instruments for metabolomics includes Magnetic Resonance Spectroscopy, LC/MS, UPLC/MS, etc., which, along with their high-throughput analysis, give insights into the metabolites and the molecular pathways involved. For instance, metabolome research has led to the discovery of the glutamate-to-glutamate ratio and aerobic glycolysis as biomarkers in breast cancer. The present review comprehends the updates in metabolomic research and its processes that contribute to breast cancer prognosis and metastasis. The metabolome holds a future, and this review is an attempt to amalgamate the present relevant literature that might yield crucial insights for creating innovative therapeutic strategies aimed at addressing metastatic breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.